BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,549,674 | -44.5% | 134,989 | -39.1% | 0.06% | -49.6% |
| Q3 2022 | $2,793,000 | +19.1% | 221,699 | 0.0% | 0.12% | +31.5% |
| Q2 2022 | $2,346,000 | -34.9% | 221,699 | 0.0% | 0.09% | -19.8% |
| Q1 2022 | $3,605,000 | +17.4% | 221,699 | 0.0% | 0.11% | +30.6% |
| Q4 2021 | $3,071,000 | +64.8% | 221,699 | +70.9% | 0.08% | +63.5% |
| Q3 2021 | $1,864,000 | -30.1% | 129,688 | -23.1% | 0.05% | -16.1% |
| Q2 2021 | $2,667,000 | +55.4% | 168,715 | 0.0% | 0.06% | +63.2% |
| Q1 2021 | $1,716,000 | -49.7% | 168,715 | -63.2% | 0.04% | -51.3% |
| Q4 2020 | $3,413,000 | +114.9% | 458,075 | -0.9% | 0.08% | +100.0% |
| Q3 2020 | $1,588,000 | -27.9% | 462,402 | 0.0% | 0.04% | -22.0% |
| Q2 2020 | $2,203,000 | +42.8% | 462,402 | -40.1% | 0.05% | +28.2% |
| Q1 2020 | $1,543,000 | – | 771,386 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 1,105,673 | $8,237,000 | 6.28% |
| Sarissa Capital Management LP | 8,175,000 | $60,903,000 | 6.22% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,980,870 | $22,207,000 | 2.78% |
| DG Capital Management, LLC | 1,075,732 | $8,014,000 | 1.70% |
| Ghost Tree Capital, LLC | 900,000 | $6,705,000 | 1.49% |
| Parkman Healthcare Partners LLC | 538,370 | $4,011,000 | 1.03% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,835,810 | $43,477,000 | 0.86% |
| Formidable Asset Management, LLC | 470,419 | $3,470,000 | 0.80% |
| KNOTT DAVID M | 219,461 | $1,635,000 | 0.74% |
| Altium Capital Management LP | 250,000 | $1,863,000 | 0.70% |